Role of the Apolipoprotein B–Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Case–Control Analysis in EPIC-Norfolk
Wim A. van der Steeg(Leiden University Medical Center), Kay‐Tee Khaw(University of Cambridge), Aeilko H. Zwinderman(Amsterdam Neuroscience), Robert Luben(University of Cambridge), Manjinder S. Sandhu(Leiden University Medical Center), Karim El-Harchaoui(Leiden University Medical Center), John J.P. Kastelein(QRx Pharma (United States)), Erik S.G. Stroes(Amsterdam University Medical Centers), S. Matthijs Boekholdt(Amsterdam Neuroscience), J. Wouter Jukema(Leiden University Medical Center), Nicholas J. Wareham(University of Cambridge), Evan A. Stein(Oncotherapeutics (United States))
Cited by 164
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews
|Journal of Clinical Epidemiology|2005|3.3k